Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NOBOX oogenesis homeobox (NOBOX)
- Target
- NOBOX
- Molecular classification
- Transcription factor, Homeobox protein
01
Overview
NOBOX oogenesis homeobox (NOBOX) is a homeobox gene that encodes a transcription factor critical for the regulation of oogenesis and folliculogenesis, especially during early ovarian follicle development[1][6]. This protein is preferentially expressed in oocytes and binds specific DNA motifs to control the expression of oocyte-specific genes, including GDF9 and POU5F1[1][2][4][6]. Mutations in NOBOX are linked to premature ovarian failure/insufficiency in humans, marking it as a significant genetic factor contributing to female infertility[1][2][3]. NOBOX is not known to be a therapeutic target for small molecules, biologics, or approved drugs, and currently no interacting drugs or direct mechanisms of pharmacological action are described[3][4]. The gene’s expression and functional integrity are vital for normal ovarian function, and it is studied for its role as a genetic biomarker in reproductive medicine[1][3][4].
- Other names
- Homeobox protein NOBOXnewborn ovary homeobox-encoding geneOG2OG2XOg2xOG-2POF5TCAG_12042
02
Biological functions
Regulation of oogenesisRegulation of oocyte-specific genesPositive regulation of transcription by RNA polymerase IISuppression of male-determining genesFolliculogenesisG2/M cell cycle arrest regulation
03
Disease associations
Premature ovarian failure (Premature ovarian insufficiency)Female infertilityOther reproductive disorders
04
Safety considerations
Genetic mutations may lead to infertility and premature ovarian failure, but there are currently no known direct safety concerns related to targeting by therapeutics, as it is not a druggable target in current practice[1][3]
05
Biomarkers
Mutations in NOBOX as a biomarker for primary ovarian insufficiency/premature ovarian failure[1][3]
Beyond the preview
Go deeper on NOBOX oogenesis homeobox (NOBOX).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOBOX oogenesis homeobox (NOBOX).